Paul Prather
Concepts (262)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptor, Cannabinoid, CB1 | 25 | 2022 | 128 | 6.310 |
Why?
| Cannabinoids | 17 | 2022 | 108 | 5.720 |
Why?
| Receptor, Cannabinoid, CB2 | 18 | 2021 | 59 | 5.140 |
Why?
| Indoles | 21 | 2021 | 287 | 3.570 |
Why?
| Naphthalenes | 14 | 2021 | 127 | 3.350 |
Why?
| Cannabinoid Receptor Agonists | 9 | 2022 | 45 | 1.850 |
Why?
| Tamoxifen | 3 | 2018 | 65 | 1.710 |
Why?
| Quinuclidines | 5 | 2020 | 42 | 1.580 |
Why?
| Selective Estrogen Receptor Modulators | 3 | 2018 | 28 | 1.300 |
Why?
| CHO Cells | 13 | 2018 | 125 | 1.260 |
Why?
| Receptors, Cannabinoid | 5 | 2022 | 21 | 1.200 |
Why?
| Morpholines | 3 | 2021 | 67 | 1.100 |
Why?
| Benzoxazines | 2 | 2021 | 18 | 1.020 |
Why?
| Binding, Competitive | 10 | 2021 | 127 | 1.010 |
Why?
| Cricetinae | 12 | 2018 | 210 | 1.000 |
Why?
| Cricetulus | 9 | 2018 | 103 | 0.990 |
Why?
| Animals | 39 | 2022 | 14624 | 0.950 |
Why?
| GTP-Binding Proteins | 4 | 2017 | 94 | 0.940 |
Why?
| Drug Inverse Agonism | 5 | 2018 | 18 | 0.930 |
Why?
| Sarcoma, Ewing | 1 | 2021 | 21 | 0.840 |
Why?
| Ligands | 10 | 2021 | 248 | 0.810 |
Why?
| Receptors, Opioid, mu | 4 | 2017 | 47 | 0.740 |
Why?
| Antineoplastic Agents | 2 | 2021 | 1296 | 0.700 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 144 | 0.700 |
Why?
| Mice | 18 | 2022 | 6414 | 0.700 |
Why?
| Designer Drugs | 3 | 2013 | 28 | 0.690 |
Why?
| Prostatic Neoplasms | 1 | 2022 | 425 | 0.650 |
Why?
| Pyrrolidines | 2 | 2018 | 84 | 0.640 |
Why?
| Endocannabinoids | 4 | 2015 | 27 | 0.600 |
Why?
| Indazoles | 3 | 2022 | 57 | 0.590 |
Why?
| Piperidines | 2 | 2017 | 102 | 0.570 |
Why?
| Cyclohexanols | 5 | 2017 | 23 | 0.570 |
Why?
| Adamantane | 3 | 2020 | 36 | 0.560 |
Why?
| Phenols | 3 | 2015 | 119 | 0.550 |
Why?
| Osteoclasts | 1 | 2018 | 472 | 0.520 |
Why?
| Glycerides | 3 | 2015 | 7 | 0.490 |
Why?
| Protein Binding | 7 | 2020 | 750 | 0.470 |
Why?
| Morphine Derivatives | 3 | 2017 | 30 | 0.460 |
Why?
| Pyrazoles | 2 | 2017 | 110 | 0.460 |
Why?
| Stilbenes | 2 | 2011 | 64 | 0.440 |
Why?
| Humans | 35 | 2022 | 53836 | 0.420 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.420 |
Why?
| Narcotic Antagonists | 1 | 2012 | 127 | 0.420 |
Why?
| Drug Tolerance | 4 | 2019 | 60 | 0.410 |
Why?
| Plant Extracts | 1 | 2013 | 193 | 0.400 |
Why?
| Analgesics, Non-Narcotic | 1 | 2012 | 142 | 0.400 |
Why?
| Pain | 5 | 2017 | 390 | 0.380 |
Why?
| Behavior, Animal | 1 | 2012 | 213 | 0.380 |
Why?
| Signal Transduction | 4 | 2022 | 1793 | 0.360 |
Why?
| Breast Neoplasms | 2 | 2016 | 1276 | 0.360 |
Why?
| Microsomes, Liver | 5 | 2020 | 219 | 0.360 |
Why?
| Curcumin | 1 | 2009 | 19 | 0.360 |
Why?
| Cannabinoid Receptor Antagonists | 4 | 2020 | 18 | 0.350 |
Why?
| Cannabinoid Receptor Modulators | 2 | 2007 | 13 | 0.350 |
Why?
| Analgesics | 3 | 2017 | 106 | 0.350 |
Why?
| Hydroxylation | 4 | 2012 | 64 | 0.350 |
Why?
| Flavonoids | 1 | 2009 | 62 | 0.350 |
Why?
| Molecular Structure | 6 | 2020 | 323 | 0.330 |
Why?
| Brain Ischemia | 3 | 2015 | 162 | 0.320 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2005 | 46 | 0.310 |
Why?
| Glucuronosyltransferase | 4 | 2019 | 157 | 0.310 |
Why?
| Cyclic AMP | 4 | 2016 | 115 | 0.310 |
Why?
| Central Nervous System | 1 | 2007 | 86 | 0.290 |
Why?
| Rats, Sprague-Dawley | 8 | 2018 | 1736 | 0.290 |
Why?
| Arachidonic Acids | 3 | 2015 | 26 | 0.280 |
Why?
| Amyotrophic Lateral Sclerosis | 1 | 2007 | 92 | 0.270 |
Why?
| Neuroprotective Agents | 1 | 2007 | 131 | 0.270 |
Why?
| Cell Membrane | 3 | 2013 | 277 | 0.270 |
Why?
| Male | 18 | 2022 | 27633 | 0.260 |
Why?
| Lignans | 2 | 2015 | 5 | 0.260 |
Why?
| Rats | 9 | 2017 | 3538 | 0.250 |
Why?
| Analgesics, Opioid | 4 | 2017 | 489 | 0.240 |
Why?
| Body Temperature | 3 | 2013 | 85 | 0.240 |
Why?
| Recombinant Proteins | 5 | 2020 | 580 | 0.240 |
Why?
| Cell Death | 2 | 2022 | 233 | 0.230 |
Why?
| Receptors, Opioid, delta | 3 | 2017 | 25 | 0.230 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 105 | 0.230 |
Why?
| Cytochrome P-450 CYP3A | 2 | 2020 | 81 | 0.230 |
Why?
| Kinetics | 5 | 2020 | 703 | 0.220 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 2016 | 13 | 0.220 |
Why?
| Substance-Related Disorders | 4 | 2018 | 668 | 0.220 |
Why?
| Cytotoxins | 1 | 2021 | 17 | 0.210 |
Why?
| Mice, Inbred Strains | 2 | 2012 | 203 | 0.210 |
Why?
| Prostate | 1 | 2022 | 113 | 0.210 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2012 | 197 | 0.200 |
Why?
| Dose-Response Relationship, Drug | 7 | 2021 | 1518 | 0.200 |
Why?
| Hyperalgesia | 2 | 2018 | 56 | 0.200 |
Why?
| Aza Compounds | 1 | 2020 | 14 | 0.200 |
Why?
| Microsomes | 1 | 2020 | 49 | 0.190 |
Why?
| Polymorphism, Genetic | 3 | 2020 | 197 | 0.180 |
Why?
| Morphine | 2 | 2017 | 98 | 0.180 |
Why?
| Benzodioxoles | 2 | 2017 | 50 | 0.180 |
Why?
| Drug Design | 2 | 2018 | 138 | 0.180 |
Why?
| Pain Management | 2 | 2017 | 156 | 0.180 |
Why?
| Cell Line, Tumor | 2 | 2021 | 1546 | 0.170 |
Why?
| Mice, Inbred C57BL | 3 | 2020 | 2028 | 0.170 |
Why?
| Oxidation-Reduction | 5 | 2020 | 387 | 0.170 |
Why?
| Hypesthesia | 1 | 2018 | 18 | 0.160 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2017 | 21 | 0.160 |
Why?
| Analgesia | 1 | 2017 | 14 | 0.160 |
Why?
| Amines | 1 | 2017 | 44 | 0.160 |
Why?
| Chromatography, High Pressure Liquid | 3 | 2020 | 403 | 0.160 |
Why?
| Down-Regulation | 2 | 2012 | 391 | 0.160 |
Why?
| Bone Marrow Cells | 1 | 2018 | 233 | 0.150 |
Why?
| Diabetes Complications | 1 | 2018 | 120 | 0.150 |
Why?
| gamma-Aminobutyric Acid | 1 | 2017 | 74 | 0.150 |
Why?
| Diabetic Nephropathies | 1 | 2017 | 78 | 0.150 |
Why?
| Isomerism | 1 | 2016 | 27 | 0.150 |
Why?
| Neuralgia | 1 | 2017 | 53 | 0.150 |
Why?
| Pentacyclic Triterpenes | 2 | 2012 | 9 | 0.140 |
Why?
| Chronic Pain | 1 | 2017 | 137 | 0.140 |
Why?
| Cell Differentiation | 1 | 2018 | 728 | 0.130 |
Why?
| Calcium Signaling | 2 | 2005 | 59 | 0.130 |
Why?
| Chemical Phenomena | 1 | 2014 | 18 | 0.130 |
Why?
| Palmitic Acids | 1 | 2014 | 7 | 0.130 |
Why?
| Ethanolamines | 1 | 2014 | 11 | 0.130 |
Why?
| Mucositis | 1 | 2014 | 8 | 0.130 |
Why?
| Glucuronides | 2 | 2012 | 56 | 0.130 |
Why?
| Transfection | 2 | 2005 | 417 | 0.130 |
Why?
| Microglia | 1 | 2015 | 135 | 0.130 |
Why?
| Disease Models, Animal | 4 | 2018 | 1684 | 0.120 |
Why?
| Enzyme Inhibitors | 3 | 2019 | 458 | 0.120 |
Why?
| Mast Cells | 1 | 2014 | 67 | 0.120 |
Why?
| Diet | 1 | 2018 | 602 | 0.120 |
Why?
| Structure-Activity Relationship | 3 | 2021 | 431 | 0.120 |
Why?
| AMP-Activated Protein Kinases | 1 | 2013 | 31 | 0.120 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 34 | 0.120 |
Why?
| Radiation Injuries, Experimental | 1 | 2014 | 124 | 0.110 |
Why?
| Anticarcinogenic Agents | 1 | 2012 | 43 | 0.110 |
Why?
| Psychotropic Drugs | 1 | 2013 | 85 | 0.110 |
Why?
| Macrophages | 1 | 2015 | 401 | 0.110 |
Why?
| YY1 Transcription Factor | 1 | 2012 | 8 | 0.110 |
Why?
| Triterpenes | 1 | 2012 | 13 | 0.110 |
Why?
| Drug Partial Agonism | 1 | 2012 | 7 | 0.110 |
Why?
| Drug Antagonism | 1 | 2012 | 10 | 0.110 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2012 | 17 | 0.110 |
Why?
| Adrenergic beta-Agonists | 1 | 2012 | 43 | 0.110 |
Why?
| Isoproterenol | 1 | 2012 | 55 | 0.110 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2018 | 141 | 0.110 |
Why?
| Receptor, erbB-2 | 1 | 2012 | 84 | 0.110 |
Why?
| Hemiterpenes | 1 | 2011 | 10 | 0.110 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 88 | 0.100 |
Why?
| Protein Transport | 1 | 2012 | 193 | 0.100 |
Why?
| Mitochondria | 1 | 2015 | 480 | 0.100 |
Why?
| Pain Measurement | 3 | 2017 | 252 | 0.100 |
Why?
| Brain Injuries | 1 | 2013 | 182 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2014 | 1114 | 0.100 |
Why?
| Superoxide Dismutase | 2 | 2013 | 159 | 0.100 |
Why?
| Repressor Proteins | 1 | 2012 | 170 | 0.100 |
Why?
| Brain | 3 | 2020 | 1420 | 0.100 |
Why?
| Antioxidants | 1 | 2013 | 296 | 0.100 |
Why?
| Alcoholism | 1 | 2013 | 256 | 0.090 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 322 | 0.090 |
Why?
| Tandem Mass Spectrometry | 1 | 2011 | 257 | 0.090 |
Why?
| Motor Activity | 1 | 2011 | 260 | 0.090 |
Why?
| Nociception | 2 | 2019 | 13 | 0.090 |
Why?
| Polyphenols | 1 | 2009 | 53 | 0.080 |
Why?
| Cannabis | 1 | 2011 | 138 | 0.080 |
Why?
| Neurons | 1 | 2012 | 492 | 0.080 |
Why?
| Pain Threshold | 2 | 2018 | 45 | 0.080 |
Why?
| MicroRNAs | 1 | 2012 | 382 | 0.080 |
Why?
| Female | 5 | 2020 | 28727 | 0.080 |
Why?
| Spinal Cord | 1 | 2007 | 161 | 0.070 |
Why?
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2005 | 8 | 0.070 |
Why?
| HL-60 Cells | 1 | 2005 | 24 | 0.070 |
Why?
| Cells, Cultured | 3 | 2015 | 1758 | 0.070 |
Why?
| Drug Synergism | 2 | 2017 | 174 | 0.070 |
Why?
| DNA, Complementary | 1 | 2005 | 150 | 0.070 |
Why?
| Biotransformation | 1 | 2005 | 109 | 0.070 |
Why?
| Bradykinin | 1 | 2005 | 20 | 0.070 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2005 | 171 | 0.070 |
Why?
| Up-Regulation | 1 | 2007 | 518 | 0.060 |
Why?
| Mice, Transgenic | 1 | 2007 | 705 | 0.060 |
Why?
| Survival Rate | 1 | 2007 | 974 | 0.060 |
Why?
| Kidney Tubules, Proximal | 1 | 2005 | 140 | 0.060 |
Why?
| Blotting, Western | 1 | 2005 | 698 | 0.060 |
Why?
| Disease Progression | 1 | 2007 | 911 | 0.060 |
Why?
| Liver | 3 | 2020 | 1273 | 0.060 |
Why?
| Protein Conformation | 1 | 2004 | 226 | 0.060 |
Why?
| Stereoisomerism | 2 | 2013 | 112 | 0.060 |
Why?
| Epithelial Cells | 1 | 2005 | 283 | 0.060 |
Why?
| RNA, Messenger | 1 | 2007 | 1276 | 0.060 |
Why?
| Neoplasms | 1 | 2012 | 1298 | 0.050 |
Why?
| Inflammation | 1 | 2007 | 671 | 0.050 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2021 | 21 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2012 | 315 | 0.050 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 24 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2020 | 84 | 0.050 |
Why?
| Treatment Outcome | 2 | 2013 | 5645 | 0.050 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.040 |
Why?
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 10 | 0.040 |
Why?
| Nociceptors | 1 | 1998 | 17 | 0.040 |
Why?
| Time Factors | 2 | 2019 | 3282 | 0.040 |
Why?
| Cell Line | 2 | 2016 | 1169 | 0.040 |
Why?
| Streptozocin | 1 | 2018 | 27 | 0.040 |
Why?
| Monoacylglycerol Lipases | 1 | 2017 | 1 | 0.040 |
Why?
| Intestines | 1 | 2020 | 211 | 0.040 |
Why?
| Narcotics | 1 | 1998 | 111 | 0.040 |
Why?
| Sex Factors | 1 | 2020 | 784 | 0.040 |
Why?
| Drug Evaluation, Preclinical | 1 | 2017 | 158 | 0.040 |
Why?
| Receptors, Opioid, kappa | 1 | 2016 | 40 | 0.040 |
Why?
| Cell Respiration | 1 | 2015 | 55 | 0.030 |
Why?
| Phenotype | 1 | 2018 | 824 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 278 | 0.030 |
Why?
| Amides | 1 | 2014 | 43 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Capsules | 1 | 2013 | 33 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 14 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Powders | 1 | 2013 | 33 | 0.030 |
Why?
| Tablets | 1 | 2013 | 32 | 0.030 |
Why?
| Membranes | 1 | 2013 | 19 | 0.030 |
Why?
| Conditioning, Classical | 1 | 2013 | 41 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 2014 | 173 | 0.030 |
Why?
| Free Radical Scavengers | 1 | 2013 | 38 | 0.030 |
Why?
| Self Administration | 1 | 2013 | 98 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 56 | 0.030 |
Why?
| Hypothermia | 1 | 2013 | 41 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 58 | 0.030 |
Why?
| Cerebral Infarction | 1 | 2013 | 32 | 0.030 |
Why?
| Catalase | 1 | 2013 | 74 | 0.030 |
Why?
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 35 | 0.030 |
Why?
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
| Sp Transcription Factors | 1 | 2012 | 6 | 0.030 |
Why?
| Conditioning, Operant | 1 | 2013 | 108 | 0.030 |
Why?
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 47 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 26 | 0.030 |
Why?
| Psychomotor Performance | 1 | 2013 | 165 | 0.030 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 4 | 0.030 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 75 | 0.030 |
Why?
| Intestinal Mucosa | 1 | 2014 | 289 | 0.030 |
Why?
| Prenylation | 1 | 2011 | 3 | 0.030 |
Why?
| Sesquiterpenes | 1 | 2013 | 91 | 0.030 |
Why?
| Metabolic Detoxication, Phase II | 1 | 2011 | 12 | 0.030 |
Why?
| rab GTP-Binding Proteins | 1 | 2012 | 39 | 0.030 |
Why?
| Protein Isoforms | 1 | 2012 | 136 | 0.030 |
Why?
| Mice, Nude | 1 | 2012 | 282 | 0.030 |
Why?
| Transcriptome | 1 | 2014 | 350 | 0.030 |
Why?
| Biological Availability | 1 | 2011 | 135 | 0.030 |
Why?
| Glucuronidase | 1 | 2011 | 47 | 0.030 |
Why?
| Cerebral Cortex | 1 | 2013 | 236 | 0.030 |
Why?
| Phosphorylation | 1 | 2013 | 614 | 0.030 |
Why?
| HEK293 Cells | 1 | 2012 | 249 | 0.030 |
Why?
| Methamphetamine | 1 | 2013 | 236 | 0.020 |
Why?
| Central Nervous System Stimulants | 1 | 2013 | 254 | 0.020 |
Why?
| Glucose | 1 | 2013 | 347 | 0.020 |
Why?
| Ethanol | 1 | 2013 | 327 | 0.020 |
Why?
| Models, Molecular | 1 | 2011 | 426 | 0.020 |
Why?
| Oxygen | 1 | 2013 | 367 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 490 | 0.020 |
Why?
| Cell Proliferation | 1 | 2012 | 1116 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 881 | 0.020 |
Why?
| Hepatocytes | 1 | 2009 | 217 | 0.020 |
Why?
| Oxidative Stress | 1 | 2013 | 955 | 0.020 |
Why?
| Models, Biological | 1 | 2011 | 840 | 0.020 |
Why?
| Apoptosis | 1 | 2012 | 1323 | 0.020 |
Why?
| Virulence Factors, Bordetella | 1 | 1998 | 8 | 0.010 |
Why?
| Pertussis Toxin | 1 | 1998 | 9 | 0.010 |
Why?
| Injections, Spinal | 1 | 1998 | 19 | 0.010 |
Why?
| Formaldehyde | 1 | 1998 | 49 | 0.010 |
Why?
| Nervous System | 1 | 1998 | 34 | 0.010 |
Why?
| Animals, Newborn | 1 | 1998 | 405 | 0.010 |
Why?
|
|
Prather's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|